在患有重大冠状动脉疾病的患者中,PCI与TAVR之前的保守管理相比:全国性的仪器变量分析
Antros Louca1,2, Petur Petursson1,2, Joakim Sundström1,2
1Department of Cardiology (A.L., P.P., J.S., K.S., M.M., D.I., S.V., A.M., O.A., A. Rawshani, T.R.), Sahlgrenska University Hospital, Gothenburg, Sweden.
Circulation. Cardiovascular interventions
|February 20, 2026
概括
在过导管大动脉置换 (TAVR) 之前的皮肤冠状动脉干预 (PCI) 并没有改善存活率或减少紧急再血管化. 然而,PCI减少了非紧急的再血管化,但增加了出血风险,需要个性化患者管理.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 心血管外科心血管外科
背景情况:
- 在接受过导管大动脉置换 (TAVR) 的患者中,冠状动脉疾病 (CAD) 的最佳管理还没有得到很好的定义.
- 有限的证据支持在TAVR之前进行例行皮肤冠状动脉干预 (PCI).
研究的目的:
- 评估在TAVR之前PCI的临床益处,与显著CAD患者的保守管理相比.
- 使用全国范围的瑞典注册数据进行全面分析.
主要方法:
- 对2578名接受TAVR (2008-2023) 的瑞典患者进行了观察性研究,这些患者患有显著的CAD.
- 在TAVR之前接受PCI的1182名患者和保守管理的1396名患者之间的比较.
- 用于减轻混因素的仪器变量方法.
主要成果:
- 在TAVR之前的PCI在初级复合结果 (死亡率,心肌梗塞,紧急再血管) 中没有显著差异.
- PCI与任何重血管化的风险降低相关 (HR 0.46),但增加出血风险 (OR 1.59).
- 在所有原因死亡率,心肌梗塞,心血管死亡,中风或紧急再血管化方面没有观察到显著差异.
结论:
- 在TAVR之前的PCI并没有提高生存率或减少急需的再血管化需求.
- PCI减少了非紧急的再血管化,但增加了出血并发症.
- 个性化治疗决策至关重要,平衡缺血和出血风险,考虑到TAVR后冠状动脉接触.
相关概念视频
Coronary Artery Disease V: Interprofessional Care
320
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
320
Angina IV: Management
330
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
330
Aortic Regurgitation III: Medical Management
479
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
479
Acute Coronary Syndrome III: Diagnostic Studies
312
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
312
Mitral Stenosis III: Medical Management
335
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
335
Coronary Artery Disease IV: Preventive Measures
741
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
741


